A new milestone in ten months! Asaan Pharma was included in the Hang Seng Composite Index and other three major indices.

On August 17, ASX PHARMACEUTICAL announced that, based on the latest quarterly adjustment results of the index series announced by Hang Seng Index Limited, the company was included in the Hang Seng Composite Index, the Hang Seng Hong Kong List Biotechnology Index and the Hang Seng Healthcare Index, effective September 7 this year.
The Hang Seng Composite Index is one of the important indices of the Hong Kong stock market and can be used as a benchmark for issuing index funds, mutual funds and performance measures using the weighted method of market capitalization in circulation, with 485 shares now in the stock market.
the index covers the highest total market capitalisation of securities listed on the Main Board of the Hong Kong Stock Exchange, providing investors with a comprehensive indicator of the Hong Kong market.
Hang Seng Healthcare Index reflects the overall performance of Hong Kong listed companies with healthcare as their main business income, with 12 new component stocks added to the adjustment, representing 47 new components.
The Hang Seng Hong Kong-listed Biotechnology Index, which is designed to reflect the overall performance of Hong Kong-listed biotech companies, added six component stocks and now includes 43 premium biotech shares, including Asah Pharmaceuticals.
The above three indices provide an important reference for the Hong Kong stock market, especially note that a total of five biopharmaceutical companies listed through Chapter 18A of the Listing Rules, including Asason Pharmaceuticals, were included in the Hang Seng Composite Index, demonstrating the concern and recognition of the capital market for this sector.
and Asaan Pharmaceuticals is one of two biopharmaceutical companies that have been selected in both indexes.
Pharmaceuticals was successfully listed in Hong Kong in October 2019, becoming the first new drug for original small molecules.
the listing of the company, further comprehensive promotion of global clinical development, research and development progress frequently.
, the company submitted its first application for a new drug listing (NDA), a milestone and an important step from a research and development company to a product-listed company.
Dr. Yang Dajun, Chairman and CEO of Yasheng Pharmaceuticals, said, "The company's selection as an important part of the above-mentioned index series fully reflects the recognition and confidence of the capital market in the company's business, stock liquidity and development prospects, and helps the company to introduce more investors and enhance the company's visibility in the capital market."
we will continue to seize the major opportunities in the development of the biopharmaceutical industry, develop our research and development and operational strengths, strive to provide safe and effective treatment options for patients worldwide, and strive to create value for our shareholders.
" About Asah Pharmaceuticals Asah Pharmaceuticals is a China-based, global-oriented clinical development stage of the original innovative pharmaceutical research and development enterprises, committed to the cancer, hepatitis B and aging-related diseases and other therapeutic areas of the development of innovative drugs.
28, 2019, Asasin Pharma was listed on the Main Board of the Hong Kong Stock Exchange.
assus Pharmaceuticals has an independently constructed protein-protein interaction targeting drug design platform, which is at the forefront of new drug research and development in the apoptosis path.
has established eight new class 1 small molecule pharmaceutical products that are in clinical development, including inhibitors for apoptotic pathway-critical proteins such as Bcl-2/Bcl-xL, IAP or MDM2-p53;
currently conducting more than 30 Phase I/II clinical trials in China, the United States and Australia.
HQP1351, the core variety used to treat drug-resistant chronic myeloid leukemia, has been certified by the FDA for fast-track and orphan drugs, and has submitted applications for new drug listing in China.
another important variety of APG-2575 recently also obtained FDA orphan drug certification.
.